Sector News

AstraZeneca's $4 billion Acerta deal endorsed by orphan drug status

February 29, 2016
Life sciences

AstraZeneca’s bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special “orphan” status to the key experimental drug involved.

The drugmaker said on Thursday that the European Medicines Agency had recommended acalabrutinib as an orphan product for chronic lymphocytic leukaemia or small lymphocytic lymphoma, mantle cell lymphoma and lymphoplasmacytic lymphoma.

Orphan status is awarded to medicines promising significant benefit in the treatment of rare, life-threatening diseases and the designation provides companies with special development and market exclusivity incentives.

AstraZeneca bought control of Acerta to get its hands on acalabrutinib, which it believes could generate sales of more than $5 billion a year. The drug is currently in the final stages of clinical development for various blood cancers.

Acalabrutinib works in a similar way to AbbVie and Johnson & Johnson’s Imbruvica. But AstraZeneca reckons it has fewer side effects than Imbruvica and potentially better efficacy. Rival drugs are further behind in development.

Acerta shareholders will have the option to sell the remaining 45 percent of shares in the biotech company to AstraZeneca for approximately $3 billion once acalabrutinib has been approved in both the United States and Europe.

The new medicine is a so-called Burton’s tyrosine kinase inhibitor that targets an array of blood cancers and potentially some solid tumors. It may also help in autoimmune diseases such as rheumatoid arthritis and lupus.

By Ben Hirschler; editing by Jason Neely

Source: Reuters

Related News

February 28, 2021

UCB taps Microsoft to accelerate drug discovery, clinical trials

Life sciences

The deal will see Microsoft use its capabilities in computational services, cloud computing and artificial intelligence to support drug discovery and development at UCB.

February 28, 2021

GSK to close two UK antibiotics manufacturing sites

Life sciences

The planned closures come as GSK has agreed to sell its cephalosporins antibiotics business to Sandoz, a division of Swiss pharma firm Novartis, for as much as US$500m.

February 28, 2021

Colorcon launches TiO2-free supplement coating

Life sciences

“The launch of these new formulations provides the nutritional market with much-needed alternative coating systems that address clean label consumer preferences and are easy to implement,” says Kelly Boyer, vice president film coatings at Colorcon.

Send this to a friend